Palbociclib Expanded access program(EAP) is initiated by Pfizer in USA for investigational CDK 4/6 inhibitor.With this programme Palbociclib in combination with letorozole is made available for women withHR+( Hormone receptor positive), and HER2-(Human epidermal growth facotr receptor 2 negative) advanced breast CANCER for whom this letrozole is considered as appropiate therapy/treatment.
Pabociclib when administered orally,it selective inhibits CDK's 4 and 6 (cyclin dependent kinase)to regain cell cycle control and will block further cell proliferation.
Pabociclib when administered orally,it selective inhibits CDK's 4 and 6 (cyclin dependent kinase)to regain cell cycle control and will block further cell proliferation.